Suppr超能文献

联合用药 I 期试验的连续重新评估法设计规范。

Specifications of a continual reassessment method design for phase I trials of combined drugs.

作者信息

Wages Nolan A, Conaway Mark R

机构信息

Division of Translational Research and Applied Statistics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.

出版信息

Pharm Stat. 2013 Jul-Aug;12(4):217-24. doi: 10.1002/pst.1575. Epub 2013 Jun 3.

Abstract

In studies of combinations of agents in phase I oncology trials, the dose-toxicity relationship may not be monotone for all combinations, in which case the toxicity probabilities follow a partial order. The continual reassessment method for partial orders (PO-CRM) is a design for phase I trials of combinations that leans upon identifying possible complete orders associated with the partial order. This article addresses some practical design considerations not previously undertaken when describing the PO-CRM. We describe an approach in choosing a proper subset of possible orderings, formulated according to the known toxicity relationships within a matrix of combination therapies. Other design issues, such as working model selection and stopping rules, are also discussed. We demonstrate the practical ability of PO-CRM as a phase I design for combinations through its use in a recent trial designed at the University of Virginia Cancer Center.

摘要

在肿瘤学I期试验中对联合用药进行研究时,并非所有联合用药的剂量-毒性关系都是单调的,在这种情况下,毒性概率遵循偏序关系。偏序连续重新评估方法(PO-CRM)是一种用于联合用药I期试验的设计方法,它依赖于识别与偏序相关的可能的全序关系。本文讨论了在描述PO-CRM时以前未涉及的一些实际设计考虑因素。我们描述了一种选择可能排序的适当子集的方法,该方法是根据联合治疗矩阵内已知的毒性关系制定的。还讨论了其他设计问题,如工作模型选择和停止规则。我们通过弗吉尼亚大学癌症中心最近设计的一项试验中对PO-CRM的应用,展示了其作为联合用药I期设计的实际能力。

相似文献

2
Dose-finding design for multi-drug combinations.多药物组合的剂量发现设计。
Clin Trials. 2011 Aug;8(4):380-9. doi: 10.1177/1740774511408748. Epub 2011 Jun 7.
6
pocrm: an R-package for phase I trials of combinations of agents.pocrm:用于联合用药的 I 期临床试验的 R 包。
Comput Methods Programs Biomed. 2013 Oct;112(1):211-8. doi: 10.1016/j.cmpb.2013.05.020. Epub 2013 Jul 18.
7
10
Shift models for dose-finding in partially ordered groups.部分有序组中剂量探索的转换模型。
Clin Trials. 2019 Feb;16(1):32-40. doi: 10.1177/1740774518801599. Epub 2018 Oct 11.

引用本文的文献

9
A surface-free design for phase I dual-agent combination trials.用于I期双药联合试验的无表面设计
Stat Methods Med Res. 2020 Oct;29(10):3093-3109. doi: 10.1177/0962280220919450. Epub 2020 Apr 27.

本文引用的文献

2
Dose-finding design for multi-drug combinations.多药物组合的剂量发现设计。
Clin Trials. 2011 Aug;8(4):380-9. doi: 10.1177/1740774511408748. Epub 2011 Jun 7.
3
Continual reassessment method for partial ordering.偏序的连续重新评估方法
Biometrics. 2011 Dec;67(4):1555-63. doi: 10.1111/j.1541-0420.2011.01560.x. Epub 2011 Mar 1.
4
Retrospective robustness of the continual reassessment method.连续重新评估法的回顾性稳健性。
J Biopharm Stat. 2010 Sep;20(5):1013-25. doi: 10.1080/10543400903315732.
5
Model calibration in the continual reassessment method.序贯评估法中的模型校准
Clin Trials. 2009 Jun;6(3):227-38. doi: 10.1177/1740774509105076.
9
Designs for single- or multiple-agent phase I trials.单药或多药I期试验的设计。
Biometrics. 2004 Sep;60(3):661-9. doi: 10.1111/j.0006-341X.2004.00215.x.
10
Non-parametric optimal design in dose finding studies.剂量探索研究中的非参数优化设计。
Biostatistics. 2002 Mar;3(1):51-6. doi: 10.1093/biostatistics/3.1.51.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验